[Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?]

Progress in clinical characteristics of high myopia with primary open-angle glaucoma

High myopia (HM) is a significant risk factor for the occurrence and progression of primary open-angle glaucoma (POAG). Identification with POAG in the HM population is an emergent challenge. Patients with HM have a significantly higher probability of complicating POAG than those without HM. When HM is associated with POAG, the changes to the fundus caused by both of them are confused with each other, making the diagnosis of early glaucoma difficult. This article reviews available researches on HM with POAG, summarizing the characteristics of the fundus structure such as epidemiology, intraocular pressure, optic disc, ganglion cell layer, retinal nerve fiber layer, vascular density, and visual field.

Impact of intraocular pressure fluctuations on progression of normal tension glaucoma

AIM

To investigate short- and long-term intraocular pressure (IOP) fluctuations and further ocular and demographic parameters as predictors for normal tension glaucoma (NTG) progression.

METHODS

This retrospective, longitudinal cohort study included 137 eyes of 75 patients with NTG, defined by glaucomatous optic disc or visual field defect with normal IOP (<21 mm Hg), independently from therapy regimen. IOP fluctuation, mean, and maximum were inspected with a mean follow-up of 38mo [standard deviation (SD) 18mo]. Inclusion criteria were the performance of minimum two 48-hour profiles including perimetry, Heidelberg retina tomograph (HRT) imaging, and optic disc photographs. The impact of IOP parameters, myopia, sex, cup-to-disc-ratio, and visual field results on progression of NTG were analyzed using Cox regression models. A sub-group analysis with results from optical coherence tomography (OCT) was performed.

RESULTS

IOP fluctuations, average, and maximum were not risk factors for progression in NTG patients, although maximum IOP at the initial IOP profile was higher in eyes with progression than in eyes without progression (P=0.054). The 46/137 (33.5%) eyes progressed over the follow-up period. Overall progression (at least three progression confirmations) occurred in 28/137 eyes (20.4%). Most progressions were detected by perimetry (36/46). Long-term IOP mean over all pressure profiles was 12.8 mm Hg (SD 1.3 mm Hg); IOP fluctuation was 1.4 mm Hg (SD 0.8 mm Hg). The progression-free five-year rate was 58.2% (SD 6.5%).

CONCLUSION

Short- and long-term IOP fluctuations do not result in progression of NTG. As functional changes are most likely to happen, NTG should be monitored with visual field testing more often than with other devices.

[The role of citicoline in glaucoma]

Hintergrund

In den letzten Jahren wurde in vielen experimentellen und klinischen Studien gezeigt, dass bei der Glaukomerkrankung die neuronale Degeneration nicht nur auf der Höhe von Netzhaut und Sehnerv, sondern im Verlauf der gesamten Sehbahn und des Gehirns erfolgt.

Fragestellung

Dargestellt werden die neuroprotektive Wirkung und ihre Mechanismen von Citicolin bei der Glaukomerkrankung.

Material und Methode

Vor dem Hintergrund der Neuroanatomie, des Neuroimaging und der Pathogenese der Glaukomerkrankung wird die Relevanz erläutert. Die Daten der experimentellen und klinischen Studien werden dargelegt und ein Fazit für die klinische Anwendung gezogen.

Ergebnisse

Citicolin wirkt neuroprotektiv über glaukomrelevante Mechanismen. Die neuroprotektive Wirkung von Citicolin bei Offenwinkelglaukomen ist funktionell und morphologisch nachweisbar. Sie ist unabhängig vom Glaukomschaden und Augeninnendruck und tritt i. d. R. erst nach einem Jahr auf. Die Effekte von oralem Citicolin treten bei einer Tagesdosis von 500–1000 mg auf. Die Einnahme von Citicolin kann dauerhaft oder in Zyklen erfolgen. In den Studien traten bei der Einnahme von Citicolin keine Nebenwirkungen auf. Citicolin kann kognitive Leistungen und somit Therapieadhärenz sowie die Lebensqualität bei Glaukompatienten verbessern

Schlussfolgerung

Diese relativ alte nootrope Substanz, welche jetzt als Nahrungsergänzungsmittel vertrieben wird, scheint eine wertvolle Ergänzung zur konventionellen Therapie der Glaukomerkrankung und eine rationale Option zur Neuroprotektion und Prophylaxe zu sein.

Assessment of the Efficacy of Microinvasive Glaucoma Surgery Techniques using an Oculopression Stress Test

BACKGROUND

Glaucoma is one of the most common causes of blindness worldwide. The only evidence-based treatment to slow down the progression of glaucoma is the reduction of intraocular pressure (IOP) using local medication or through surgery. During the last years, a large number of microinvasive glaucoma surgery techniques (MIGS) has been developed, in order to reduce the IOP in glaucoma patients safely and effectively. Until now, efficacy of MIGS has been assessed mainly according to the postoperative IOP and the number of medications used. Results from long-term studies are rare or not available in the majority of the cases. In order to better evaluate the functionality of MIGS, a new examination method has been developed with the help of a new oculopressor device. In this study the efficacy of different MIGS techniques will be examined using the new oculopressor.

MATERIAL/METHODS

At first, glaucoma patients that had previously received a MIGS surgery (iStent inject, XEN Stent, ELT) were examined with the new oculopression test. Their results were compared with those of non-operated patients and healthy individuals. Overall, 38 healthy subjects (group 1), 10 non-operated patients (group 2), 19 patients after iStent inject implantation (group 3), 14 patients after XEN Stent implantation (group 4) and 5 patients after ELT (group 5) were examined. The new examination measures the IOP-reduction that occurs after oculopression and can be seen as an indirect measurement of the outflow facility of the eye.

RESULTS

The IOP-reduction after oculopression differed among the study groups. Non-operated patients showed a significantly lower IOP-reduction compared to healthy individuals. Patients after iStent inject and XEN stent implantation showed a larger reduction of IOP after oculopression in relation to non-operated patients and their results approximated those of healthy individuals. These patients needed fewer medications postoperatively in relation to non-operated patients. Patients after ELT showed postoperatively a smaller reduction of IOP after oculopression compared to iStent inject and XEN stent patients.

CONCLUSION

MIGS can increase the outflow facility of the eye in patients with glaucoma. Though ELT had the lowest impact on the aqueous outflow among the studied procedures in this study. The new test can help in the evaluation of current and further development of new MIGS in the future.

Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma

AIM

To evaluate intraocular pressure (IOP)-lowering effect and ocular tolerability of brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies in the management of primary open angle glaucoma.

METHODS

Each drug was administered for two months, after which a circadian tonometric curve was recorded using a Goldmann applanation tonometer. Ocular discomfort (conjunctival hyperemia, burning or stinging, foreign body sensation, itching, ocular pain) of each eye was assessed by the subject on a standardized ocular discomfort scale.

RESULTS

Among the three study groups, there were no significant differences in the mean baseline IOP measurements, mean 2(nd) mo IOP measurements, and mean (%) change of IOPs from baseline. Among the three study groups, there were no significant differences in the mean IOP measurements obtained at circadian tonometric curves at baseline and at two months controls. In sum brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies showed similar effects on IOP levels.

CONCLUSION

Brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies showed similar lowering efficaties on IOP levels whereas there was no any difference between each other.